Therapeutic approach to treat virus-induced lung failure for severe COVID-19 shows promise in clinical trial
A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery ...
News Medical on MSN22h
FasL inhibitor speeds recovery and reduces mortality in severe COVID-19 patients
A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery ...
Medindia20h
Faster Recovery, Fewer Deaths: The Latest COVID-19 Therapeutic Innovation
The latest COVID-19 treatment, using an inhibitor of the Fas ligand (FasL), also known as CD95 ligand (CD95L), speeds up ...
Le Lézard19h
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease
Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...
SOLIGENIX, INC.: Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease
Study DUS-AUBD-01 opens patient enrollment PRINCETON, N.J., Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage ...
Armed robbery in Revesby21h
New Therapy for COVID-19: Speeds Recovery, Cuts Deaths
The study 'Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe ...